Voyager’s Gene Therapy to Enter Phase 2/3 Trial Program for Advanced Parkinson’s Disease – Parkinson’s News Today
Parkinson’s News Today |
Voyager’s Gene Therapy to Enter Phase 2/3 Trial Program for Advanced Parkinson’s Disease
Parkinson’s News Today Voyager Therapeutics will soon initiate a global Phase 2/3 clinical trial program to evaluate its VY-AADC gene therapy for the treatment of advanced Parkinson’s disease. The trial follows approval by the U.S. Food and Drug Administration of the company … MRI Interventions Recognizes FDA Clearance of Voyager’s Investigational New Drug Application for VY-AADC …GlobeNewswire (press release) |
Outer Places |
UPenn researchers want to launch the US’s 1st CRISPR trial in humans: 6 things to know
Becker’s Hospital Review A team of researchers from Philadelphia-based University of Pennsylvania expect to receive FDA clearance to conduct the first CRISPR trial treating human patients in the U.S., according to The Wall Street Journal. However, due to a less stringent … China Has Already Used CRISPR to Edit 86 People’s DNA Despite WarningsOuter Places NIH Commits $190M to Somatic Gene-Editing Tools/Tech ResearchGenetic Engineering & Biotechnology News |